Posted by Michael Wonder on 18 Aug 2019
Roche drug approval offers a glimpse at the future of cancer treatment
15 August 2019 - The FDA on Thursday approved Roche’s cancer drug Rozlytrek for patients with any kind of tumour that tests positive for one kind of genetic alteration, known as NTRK, and for non-small cell lung cancer that tests positive for another genetic alteration, ROS1.
It’s the third time that the FDA has approved a cancer drug not based on where the tumour showed up in the body but on its genetic makeup.
It’s part of an emerging picture of the future of cancer treatment — one that has been long imagined.
